Current Edition

a CSL Behring

CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this year

In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent …

Continue Reading →
Biocon

Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses

Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …

Continue Reading →
divestment

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz

Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …

Continue Reading →
antibody drugs

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …

Continue Reading →